Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2,3,4,5,6-Pentafluorobenzyl)-4-sulfamoyl-benzamide is a synthetic small molecule belonging to the class of n-benzylbenzamides. It features a benzamide core substituted with a pentafluorobenzyl group and a sulfamoyl moiety. This compound is primarily studied as an experimental inhibitor of carbonic anhydrase 2 (CA II), an enzyme involved in pH regulation and fluid balance in tissues. The compound exhibits high affinity for CA II (reported Kd ~2 nM), suggesting potential utility as a research tool or lead structure for developing carbonic anhydrase inhibitors. There are no approved therapeutic indications or clinical trials reported for this molecule[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on n-(2,3,4,5,6-pentafluorobenzyl)-4-sulfamoyl-benzamide.